Literature DB >> 2364078

Kinetics of arginine-vasopressin uptake at the blood-brain barrier.

B V Zlokovic1, S Hyman, J G McComb, M N Lipovac, G Tang, H Davson.   

Abstract

Uptake of arginine-vasopressin, VP, at the luminal side of the blood-brain barrier (BBB) was studied by means of an in situ brain perfusion technique in the guinea-pig. Kinetic experiments revealed a saturable peptide influx into the parietal cortex, caudate nucleus and hippocampus with Km between 2.1 and 2.7 microM, and Vmax ranging from 4.9 to 5.6 pmol.min-1.g-1. The non-saturable component, Kd, was not significantly different from zero. Influx of VP into the brain was not altered by the presence of the peptide fragments: VP-(1-8), pressinoic acid and [pGlu4,Cyt6]VP-(4-9) at 4.5 microM, nor yet by the aminopeptidase inhibitor, bestatin (0.5 mM) and the L-amino acid transport system substrates, L-tyrosine and L-phenylalanine at 5 mM. At a perfusate concentration of 4.5 microM, the V1-vasopressinergic receptor antagonist, d(CH2)5[Tyr(Me)2]VP, reduced VP influx; regional Ki values, assuming that the observed inhibitions were purely competitive, ranged between 4.7 and 8.5 microM. It is concluded that there is an apparent cerebrovascular permeability to circulating VP due to the presence of a carrier-mediated transport system for the peptide located at the luminal side. The mechanism for VP BBB uptake exhibits no affinity for peptide fragments and large neutral amino acids, but requires reception of the intact molecule, which may be the same initial step for both the BBB VP transporter and the V1-receptor.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2364078     DOI: 10.1016/0005-2736(90)90097-8

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  25 in total

1.  A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease.

Authors:  Rashid Deane; Itender Singh; Abhay P Sagare; Robert D Bell; Nathan T Ross; Barbra LaRue; Rachal Love; Sheldon Perry; Nicole Paquette; Richard J Deane; Meenakshisundaram Thiyagarajan; Troy Zarcone; Gunter Fritz; Alan E Friedman; Benjamin L Miller; Berislav V Zlokovic
Journal:  J Clin Invest       Date:  2012-03-12       Impact factor: 14.808

Review 2.  Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders.

Authors:  Berislav V Zlokovic
Journal:  Nat Rev Neurosci       Date:  2011-11-03       Impact factor: 34.870

3.  Multiple sites of vasopressin synthesis in the injured brain.

Authors:  Joanna Szmydynger-Chodobska; Brian J Zink; Adam Chodobski
Journal:  J Cereb Blood Flow Metab       Date:  2010-10-20       Impact factor: 6.200

Review 4.  Development of neuropeptide drugs that cross the blood-brain barrier.

Authors:  Richard D Egleton; Thomas P Davis
Journal:  NeuroRx       Date:  2005-01

Review 5.  Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems.

Authors:  Akira Tsuji
Journal:  NeuroRx       Date:  2005-01

Review 6.  Focused ultrasound-mediated drug delivery through the blood-brain barrier.

Authors:  Alison Burgess; Kairavi Shah; Olivia Hough; Kullervo Hynynen
Journal:  Expert Rev Neurother       Date:  2015-05       Impact factor: 4.618

7.  Altered folate binding protein expression and folate delivery are associated with congenital hydrocephalus in the hydrocephalic Texas rat.

Authors:  Alicia Requena Jimenez; Naila Naz; Jaleel A Miyan
Journal:  J Cereb Blood Flow Metab       Date:  2018-05-25       Impact factor: 6.200

Review 8.  Cerebrovascular permeability to peptides: manipulations of transport systems at the blood-brain barrier.

Authors:  B V Zlokovic
Journal:  Pharm Res       Date:  1995-10       Impact factor: 4.200

Review 9.  Brain metabolism in health, aging, and neurodegeneration.

Authors:  Simonetta Camandola; Mark P Mattson
Journal:  EMBO J       Date:  2017-04-24       Impact factor: 11.598

Review 10.  New therapeutic targets in the neurovascular pathway in Alzheimer's disease.

Authors:  Berislav V Zlokovic
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.